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Variations in the S100b gene may be instrumental in producing a continuum from mild
cognitive decline to overt dementia. After screening 25 single nucleotide polymorphisms
(SNPs) in S100b, we observed association of the rs2300403 intron 2 SNP with poorer cognitive
function in three independent populations. Moreover, we detected a significant association of
this SNP with increased risk of developing dementia or Alzheimer’s disease (AD) in six
independent populations, especially in women and in the oldest. Furthermore, we char-
acterised a new primate-specific exon within intron 2 (the corresponding mRNA isoform was
called S100b2). S100b2 expression was increased in AD brain compared with controls, and the
rs2300403 SNP was associated with elevated levels of S100b2 mRNA in AD brains, especially in
women. Therefore, this genetic variant in S100b increases the risk of low cognitive
performance and dementia, possibly by favouring a splicing event increasing S100b2 isoform
expression in the brain.
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Introduction
In many individuals, an initial cognitive impairment
inevitably and progressively leads to dementia, of
which Alzheimer’s disease (AD) is the principal
cause. A continuum may exist ranging from slight
and subtle memory loss through overt dementia.1 If
this is so, it is probable that shared environmental and
genetic susceptibility factors may relate these two
entities. With regard to dementia, three risk factors are
well established: age, gender and family history,
probably to be underpinned by genetic susceptibility
factors.
Until now, family history has been decoded mainly
through the study of early-onset inherited forms of
AD accounting for less than 2% of the cases. Three
genes have already been identified: amyloid precursor
protein, presenilin 1 and presenilin 2.2 However,
none of these have been associated with cognitive
decline in general ageing populations. The genetic
determinants of the most common late-onset forms of
the affection defined as sporadic (without obvious
mendelian pattern of inheritance) appears to be far
more complex. Numerous genetic susceptibility fac-
tors have been suspected. To date, only the apolipo-
protein E gene polymorphism (APOE) has been
consistently identified as a genetic determinant of
AD.3 In contrast to the early-onset AD genes, APOE
has been associated with early cognitive impairment
in ageing populations4 and may constitute a common
determinant of the suspected continuum.
Several lines of evidence prompted us to consider
whether the S100 calcium-binding protein B (S100b)
gene might also be implicated within this continuum.
First, this gene is located on chromosome 21q22.3, in
a chromosomal region consistently linked to familial
late-onset forms of AD.5 Second, S100bprotein ex-
hibits cytotoxic and neurotrophic properties.6 Third,
S100b protein interacts with the microtubule-asso-
ciated protein tau,7 and is a component of amyloı¨d
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plaques.8 Finally, S100b protein has been claimed
to be a peripheral marker of brain damage9 and of
cognitive decline following cardiac surgery.10
Thus, we undertook an in-depth genomic analysis
of S100b locus to identify genetic mechanisms or
variations of potential interest that may suggest this
gene could play a role in the continuum from
cognitive decline to dementia.
Materials and methods
Populations
The main characteristics of the populations are
described in Tables S2 and S3 (Supplementary
material). All subjects or, in those with substantial
cognitive impairment, a caregiver, legal guardian or
other proxy gave written informed consent for
participation in this study. The study protocols for
all populations were reviewed and approved by the
appropriate institutional review boards of each
country.
The ELDNOR study. The population study consisted
of individuals aged between 60 and 105 years in a
large representative sample (n = 1051), living in
retirement home, whose cognitive functions and
health status were systematically registered in the
French Elderly in the North (ELDNOR) study.11 From
this population-based study, a sub-population of
254 individuals was first used for the linkage
disequilibrium (LD) estimation between the S100b
single nucleotide polymorphisms (SNPs) and for the
systematic screening of their impact on the cognitive
performances (age = 80.678.5 years, 33% of men,
mini mental-state examination (MMSE) > 24). The
analysis of the SNPs showing a significant effect on
cognitive performances in this first screening was
next extended to 815 individuals exhibiting a
MMSE > 10. Furthermore, from this population-
based study, two groups with highly contrasted
levels of cognitive function were selected: 221
demented individuals, including all ELDNOR
subjects with a MMSE score < 10 or a diagnosis of
dementia according to criteria given in DSM-III-R
and a group of 146 control subjects, including all
ELDNOR subjects with a MMSE > 27 and no symptom
of dementia. Eighteen demented cases were
unsuccessfully genotyped for the rs2300403 SNP.
The Danish twin study. This study population is
based on participants of the population-based
nationwide survey ‘The Longitudinal Study of
Ageing Danish Twins’ (LSADT), which includes
Danish twins aged 70 years and older (n = 513, with
a MMSE > 10).12 The survey is an ongoing
longitudinal study initiated in 1995 that comprises
face-to-face interviews focusing on health and
lifestyle issues, including assessment of MMSE. The
subjects were randomly selected among those
participants from the LSADT 1997 and 1999 waves
for which both DNA and MMSE assessment were
available. Only one twin from each pair was included
in this analysis. In the Danish twin study, the
demented status was not available.
The Leiden 85-plus study. The Leiden 85-plus study
is a prospective population-based study that recruited
elderly inhabitants of Leiden (The Netherlands).13
People aged 85 years and above were enrolled
between 1987 and 1989 or between 1997 and 1999.
Cognitive functions were measured with the MMSE.
Those with a MMSE-score below 24 points were
psychiatrically examined to diagnose dementia
following DSM-III criteria or diagnoses of dementia
were gathered by reviewing medical records. DNA
was available for 1218 participants (430 men and 938
women). The impact of the rs2300403 on cognitive
performance was first assessed on 1049 individuals
exhibiting a MMSE > 10. Furthermore, from this
population-based study, two groups with highly
contrasting levels of cognitive functions were
selected: 206 individuals with a diagnosis of
dementia and 438 controls with a MMSE score
above 27 and no symptoms of dementia.
The Limeil-Bre´vannes study. Between June 1995
and March 1996, 127 patients with dementia
(characterised according to DSM-III-R criteria) were
recruited for a clinical study among individuals
hospitalised in the long-term care facility of the
Department of Gerontology of the Limeil Bre´vannes
Hospital (France).14 All patients included in this
study underwent detailed clinical examination,
MMSE score, Hachinski ischaemic score and CT
scan. Dementia was identified according to DSM-III-
R criteria. For controls, we used 190 brains from
routine autopsies carried out at the Hospices Civils
de Strasbourg (France). Selection of these controls
excluded dementia cases. All cases referred to
autopsy for neurological pathologies were also
excluded. In order to ensure the exclusion of
subclinical AD-affected cases, neuropathological
criteria were also applied to exclude tissues from
individuals presenting with a Braak stage greater than
2 (n = 59).
The Northern AD case–control study. The French AD
and control samples were Caucasian (AD cases
n = 609, controls n = 567).15 Clinical diagnosis of
probable AD was established according to the DSM-
III-R and NINCDS-ADRDA criteria. Caucasian
controls were defined as subjects without DMS-III-R
dementia criteria and with integrity of their cognitive
functions. Controls were recruited in retirement
homes or from electoral rolls (altruistic volunteers).
Five AD cases were not successfully genotyped for
rs2300403 SNPs.
The UK AD case–control study. All AD cases were
Caucasians (n = 349), ascertained from two UK
centres, the central belt of Scotland and Greater
Manchester.16 Diagnoses of definite or probable AD
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were established according to DSM-III-R and
NINDCS-ADRDA criteria. The proportion of definite
AD cases was 30%. The proportion of AD cases with
family history was 20%. The Caucasian controls
(n = 398) were collected from the same geographical
areas as the AD patients and were defined as subjects
without DSM-III-R dementia criteria and with full
integrity of their cognitive functions.
The Pittsburgh study. The Pittsburgh Study: 200
late-onset AD were from the University of Pittsburgh
Alzheimer’s Disease Research Center (ADRC).
Clinical diagnoses of the patients were made
according to the NINCDS/ADRDA criteria. The
ADRC follows a standard evaluation protocol, which
includes medical history, general medical and
neurological examinations, a psychiatric interview,
neuropsychological testing and a magnetic resonance
imaging scan. Age- and sex-matched 200 controls
were recruited from the same Western Pennsylvania
region as the cases and were determined to be
cognitively intact following extensive clinical
examination. Three controls and three AD cases
were not successfully genotyped for the rs2300403
SNP.
Brain tissues
AD brains were obtained at autopsy from 114 patients
with early- and late-onset sporadic AD accessioned
from Greater Manchester region of United Kingdom
during years 1986 and 2001 (mean age at onset =
65.9710.3 years; mean age at death = 73.179.1 years;
51% men). All patients were Caucasian. Pathological
diagnoses were made in accordance with CERAD
Neuropathological Criteria for AD. All patients were
at Braak stages 5 or 6 at time of death. Tau load in
frontal cortex was determined by image analysis in
86/114 patients after immunostaining for phosphory-
lated tau using a standard procedure with monoclonal
antibody AT8 (Innogenetics, Gent, Belgium) as pri-
mary antibody.17
As controls, we used 118 control brains presenting
Braak stages less than 3, selected from an initial set of
the 190 brains obtained from routine autopsies carried
out at the Hospices Civils de Strasbourg (France,
see description in the Limeil-Brevanne study in the
Supplementary material).
dHPLC and genotyping
All exons, intron/exon boundaries, entire intron 2
and proximal promoter of the S100b gene were
screened in 32 healthy individuals from the ELDNOR
study (see population description) for sequence
variation using denaturing high-performance liquid
chromatography (dHPLC) (Supplementary appendix,
Table S4). All variants identified by dHPLC were
confirmed by sequencing. When already referenced,
the name of the SNP was indicated (see Supplemen-
tary material, Table S5). The genotyping of 25 SNPs
was mainly performed by enzymatic digestion follow-
ing PCR amplification (see Supplementary material,
Table S4). A subpopulation of 254 individuals was
used for LD estimation between the S100b SNPs (see
Supplementary material, Figure S6) and for the
systematic screening of their impact on the cognitive
performances (MMSE > 24, see population descrip-
tion for more details).
The rs2300403 SNP was genotyped (i) by NlaIII
digestion following PCR amplification using 50-actct-
gaaccattcacggtg-30 and 50-gtctctcaccaagccctatt-30 oligo-
nucleotides (INSERM U744) or (ii) by Taqman
technology (Genoscreen, see Supplementary material,
Table S5). The 254 individuals of the ELDNOR
population were genotyped using the two technolo-
gies and no discrepancies were observed.
Detection of S100b and S100b2 mRNAs
New splicing events were detected by a computa-
tional procedure that analysed the genomic-expressed
sequence tag (EST)-mRNA pair-wise alignments.
Total RNA from brain or lymphocytes of healthy
individuals were used to detect S100b and S100b2
mRNA as well as purified lymphocytes from fresh
blood of Hamlyn’s cercopithec. The lymphocytes
were cultivated for 72 h in the presence of 0.1%
phytohaemagglutinin. Total RNA from lymphocytes
was extracted using RNeasy Mini kit (Qiagen, Courta-
boeuf, France) and DNase treatment. Reverse tran-
scription (RT) was performed from 30 ng of total RNA
treated by DNase before cDNA synthesis. Character-
isation of the new exon used four different oligonu-
cleotide sets. Expression of the normal S100b mRNA
was checked (see Supplementary material, Table S6).
Amplification products were directly sequenced
using the Taq dye terminator sequencing kit (Applied
Biosystems, Foster City, CA, USA). The correspond-
ing mRNA sequences were used to determine the
complete mRNA isoform sequences (see Supplemen-
tary material, Figure S6). The potential S100b2
protein sequence was determined using the Traduc
software (http://www.infobiogen.fr/services/analy-
seq/cgi-bin/traduc_in.pl).
Inter-species comparisons
Genomic DNA was extracted from fresh blood of Pan
troglodyte’s chimpanzees, Hamlyn’s cercopithec
(Cercopithecus hamlynis), Roloway’s cercopithec (Cer-
copithecus diana roloway) and catta lemurian. The
S100b gene has been sequenced using the human primer
sets described in Table S3 (see Supplementary material).
The intron 2 sequence was obtained from chimpanzees
and cercopithec and compared with the human
sequence using the dialign software (http://bioweb.
pasteur.fr/seqanal/interfaces/dialign2-simple.html). No
amplification was obtained from the lemurian genomic
DNA using the oligonucleotides for the amplification of
the S100b2 exonic sequence. Finally, the S100b2 exonic
sequence was searched using the BLAST software
(http://www.ncbi.nlm.nih.gov/BLAST/) in the Mus
Musculus genome.
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Real-time RT-PCR
Total RNA from brains of 84/114 AD patients (74%)
and 92/118 controls (78%) was extracted from frozen
brain tissue using phenol/chloroform protocol (TRI-
zol reagent, Invitrogen, Carlsbad, CA, USA) The
quality of total RNA was assessed using Agilent
2100 Bioanalyser and the ratio of ribosomal RNA
28S/18S systematically estimated using the Agilent
2100 Bioanalyser bio-sizing software (range from 0.0
to 1.8 in brains). RT was performed from 30 ng of total
RNA and expression was measured by real-time PCR
using Taqman technology to co-amplify cDNA from
the S100b and b-actin genes or from the S100b 2 and
b-actin genes, as described by the Supplier (Applied
Biosystems, Foster City, CA, USA).
Statistical analyses
The SAS software release 8.02 was used for statistical
analyses (SAS Institute, Cary, NC, USA). Pair-wise
LD coefficients were estimated in a subset of the
ELDNOR population with a MMSE > 24 (254 indivi-
duals, see dHPLC and genotyping section) using the
GOLD software (http://www.sph.umich.edu/csg/abe-
casis/GOLD) (see Supplementary material, Table S8).
We used Akaike Information Criterion (AIC) to
determine the best-fitting genetic model (dominant,
co-dominant or recessive).18,19 The model with the
lowest AIC reflects the best balance of goodness-of-fit
and parsimony. We consequently coded the genotypes
of the rs2300403 polymorphism as a dummy variable
according to the hypothesis of a recessive model, that
is, GG versus AGþAA genotype.
The impact of the S100b polymorphisms on MMSE
was first evaluated using a non-parametric Wilcoxon
test in the ELDNOR subpopulation (n = 254, see
description in the population section). Following
the extension of the rs1051169, rs2839355 and
rs2300403 SNPs analyses to the whole ELDNOR
study, the impact of these SNPs on MMSE was
analysed using a general linear model (MMSE
analysed as a continuous variable) to estimate the
effect of potential confounders such as age, gender or
APOE status. These complementary analyses did not
affect the results (data not shown). As the MMSE
scores did not follow a normal distribution, log-
transformation was also performed. This complemen-
tary analysis did not modify the results (data not
shown). Extended haplotype frequencies of the
different markers were estimated using the Thesias
software, as well as the impact of these haplotypes on
MMSE. The objective of the thesias software is to
performed haplotype-based association analysis in
unrelated individuals. This programme is based on
the maximum-likelihood model described in Stram
et al.20 and is linked to the SEM algorithm.21
The impact of the rs2300403 SNP in the Leiden-
85þ , Danish or combined populations was analysed
accordingly to the same schema than the one
described in the ELDNOR study (see above). The
general linear model was adjusted for age, gender,
centre and APOE status and centre when necessary.
Furthermore, as the MMSE scores did not follow a
normal distribution and to limit consequent potential
biases, the impact of the rs2300403 S100b SNP on the
cognitive function was also qualitatively analysed by
coding the MMSE score as a discontinuous variable
using the median MMSE score as a cutoff (two
categories: MMSEp25 and MMSE > 25). A multiple
logistic regression model was then performed ad-
justed for age, gender, centre and APOE status. For all
MMSE analyses, individuals exhibiting a MMSE less
than 10 were systematically excluded from these
analyses.
To study the impact of the rs2300403 SNP on
dementia and AD, a univariate analysis was first
performed using Pearson’s w2 test. Before pooled
analyses, homogeneity between populations was
tested using Breslow–Day computation.22 The impact
of the rs2300403 SNP on dementia or AD was then
estimated by multiple logistic regression models,
adjusted for age, gender, APOE status and centre
when necessary. Interactions among rs2300403,
APOE, gender or age variables were tested in logistic
regression models.
RNA is notoriously labile, highly sensitive to RNAse
and as a consequence, post-mortem delay can strongly
affect the results when studying mRNA expression.
However, to use only post-mortem delay as a potential
confounder does not allow correcting for history of
storage, transportation and/or extraction, leading to
further autolyses. To take into account these biases,
quality of total RNA and degradation was assessed
using ratio of ribosomal RNA 28S/18S measured by
the Agilent 2100 bionalyser and bio-sizing software, a
technology allowing estimation of RNA degradation
(and particularly RNAse action).23–25 An analysis of
covariance (adjusted for age and gender) using a
general linear model for comparison of S100b or
S100b2 mRNA amounts between AD cases and
controls was performed (mRNA level data was log
transformed to normalise distributions). The effect of
the rs2300403 SNP on S100b and S100b2 mRNA
levels was analysed with a non-parametric Wilcoxon
test. We also adjusted for mRNA degradation. The
results were not modified following this additional
analysis (data not shown). Correlation between S100b,
S100b2 mRNA levels and/or tau load was tested using
non-parametric Spearman statistic. As this level of
total RNA degradation (estimated by rRNA 28S/18S
ratio using Agilent 2100 Bioanalyser) may be a
potential confounder, standardised residuals of linear
regression analysis between degradation and S100b/
S100b2/b-actin ratio were also held for correlations
between tau loads and mRNA amount.26 These
complementary analyses did not affect the results as
well as complementary adjustment for age and gender
(data not shown).
Results
By bio-informatics, we detected a new splicing event
from the Unigene database (http://www.ncbi.nlm.
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nih.gov/entrez; accession number Hs.422181). This
event was observed in nine of the 285 (3.2%) S100b
ESTs/mRNAs available in this database (Figure 1b).
We confirmed the existence of this new exon of 94 bp
by RT-PCR from human brain tissues or lymphocytes
(Figure 1c,d) and we called this mRNA isoform
S100b2. The S100b2-predicted protein sequence
was 95 amino acids (aa) long, differing from S100b
isoform by the last 48 aa (Figure 1e). The S100b2
exonic sequence was found in the genome of
chimpanzees and cercopithecs, but not in that of
mice and lemurians (Figure 1e). From this observa-
tion, the promoter, exons, intron/exon boundaries and
the entire intron 2 (containing the new splicing event)
were then screened for variants by dHPLC and then
sequenced in 32 healthy subjects. Twenty-five SNPs
were identified. Nine had not been described pre-
viously.
These 25 SNPs (with allele frequencies varying
from < 1 to 47.1%; Figure 1a) were analysed with
respect to cognitive performance in 254 healthy
individuals with a MMSE > 24, ascertained from the
ELDNOR population-based study. Three of these
SNPs (rs1051169, rs2839355 and rs2300403) were
associated with lower cognitive performances (data
not shown). Covariate analyses of these three SNPs
over the whole ELDNOR population showed
rs2300403 SNP to be the one most strongly associated
with low cognitive performance (see Supplementary
material, Table S1). Further analyses confirmed this
SNP association in a Danish twin population (Table
1). A similar trend was observed in the Leiden 85-plus
population-based study (Table 1). The association of
the rs2300403 GG genotype was confirmed when the
three populations were pooled (Table 1) and this
association seemed to be independent of a dementia
or a predementia status (MMS > 24, DMMSE =0.5,
P = 0.002; MMSE > 27, DMMSE =0.3, P = 0.01). The
MMSE score was finally dichotomised using the
median score as a cutoff (p25 and > 25 in the
combined population, see Materials and methods).
Individuals bearing the GG genotype had a 70%
increased risk of low cognitive performance com-
pared with the AA carriers (OR = 1.7, 95 CI% (1.2–
2.1), P = 0.0005; Table 2). This observation was
consistent whatever the studied population (ORs
ranging from 1.5 to 2.8, data not shown). All these
data indicated that the rs2300403 SNP is associated
with lower cognitive performance in the elderly (age
at examination in the pooled population: 83.377.3
years). No significant statistical interaction between
gender, age, APOE status and the risk of low cognitive
performance was detected (data not shown).
Next, we investigated the potential impact of the
rs2300403 SNP on the risk of dementia in three
independent populations (Leiden-85þ , ELDNOR and
Limiel-Brevannes). The rs2300403 GG genotype was
consistently associated with an increased risk of
developing dementia in the three studies (ORs
ranging from 1.8 to 3.0; OR = 2.1, P = 0.001 in the
combined population; Table 3). We systematically
searched for potential statistical interaction between
gender, age, APOE status and the risk of developing
dementia. In these studies, the association of the
rs2300403 GG genotype was dependent on gender
and was only associated with an increased risk in
women (ORs ranging from 2.2 to 5.7; OR = 2.5,
P = 0.0006 in the combined population; gender inter-
action P = 0.02; Table 3 and Supplementary material,
Figure S1). All these data suggested that the
rs2300403 SNP was associated with the risk of
dementia in the elderly (age at examination in the
pooled population: 84.776.8 years), especially in
women.
Lastly, we assessed the impact of the rs2300403
polymorphism in AD, the most common cause of
dementia, in three different case–control studies. In
American and UK populations, the rs2300403 GG
genotype was associated with an increased risk of AD
(OR = 2.0, P = 0.05 and OR = 1.7, P = 0.03, respectively,
Table 3). In a northern French study, a similar trend
was observed (OR = 1.4, P = 0.10, Table 3). Analysis of
the pooled populations strongly supported a deleter-
ious effect of the GG genotype (OR = 1.7, P = 0.0009,
Table 3). We again searched for potential statistical
interaction between gender, age, APOE status and the
risk of developing AD. In these studies, the associa-
tion of the rs2300403 GG genotype was again
dependent on gender. As observed for dementia, the
rs2300403 GG genotype was consistently associated
with an increased risk of AD only in women (ORs
ranging from 1.6 to 2.2; OR = 1.9, P = 0.003 in the
combined population; gender interaction P = 0.05;
Table 3 and Supplementary material, Figure S2). An
interaction between age and the association of the
rs2300403 GG genotype with AD was jointly detected
(P = 0.008). Supporting this interaction, we observed
that patients bearing the GG genotype had a higher
age at onset compared with the AA carriers (69.979.1
versus 68.379.3, P = 0.04), this effect being more
pronounced in women (71.578.7 versus 69.19.7,
P = 0.02; gender interaction P = 0.02). Consistently, in
older AD patients (using the median age at examina-
tion of the different populations as a cutoff), the
rs2300403 GG genotype was associated with an
increased risk of developing AD (OR = 2.8,
P < 0.0001, Table 3), whereas no effect was detected
in the younger patients (OR = 1.1, not significant,
Table 3). The rs2300403 SNP may therefore increase
the risk of developing AD in elderly persons (age at
examination in the pooled population: 81.175.0
years). This observation was again consistent what-
ever the population (ORs ranging from 2.4 to 3.1; see
Supplementary material, Figure S3) and with our
observation in dementia in the elderly (age at
examination in the pooled population in the demen-
tia study: 84.776.8 years). As expected, the highest
risk of developing AD associated with the rs2300403
GG genotype was observed in the oldest women
(OR = 3.6, 95 CI% (1.9–6.8), P < 0.0001).
As the rs2300403 SNP is located in the intron
upstream from the new 100b2 isoform, we postulated
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Figure 1 Description of the S100b gene. (a) Position of SNPs within the S100b gene. (b) Organisation of the new splicing
event of the S100b gene. (c) Amplification of the S100b2 isoform using (1) the primer set 3 or (2) the primer set 1 in four AD
brain samples. (3) and (4) were respectively negative controls for primer set 3 and primer set 1 amplifications. (d)
Amplification of the S100b isoform (1–3) and S100b2 isoform (4–6; primer set 2) by RT-PCR from human brain (1 and 4),
human (2 and 5) and Cercopithec (3 and 6) lymphocytes. PCR products were systematically sequenced to confirm the
specific amplification of the mRNAs of interest. (e) Comparison of the putative protein sequences based on the different
S100b exon sequences. The mouse protein sequence was obtained from the NCBI website (BC061178). The additional exon
was successfully amplified only from human, chimpanzees (two different samples) and cercopithecs (two species: Hamlyn’s
and Roloway’s cercopithecs) genomic DNA. Variations in aa sequences are indicated in purple. The sequence of S100b
protein differed between the different species studied by only one residue at codon 63, whereas the putative S100b2 protein
may differ by six aa between cercopithecs and humans (chimpanzee possessed the same S100b2 aa sequence as humans).
These data indicated that the retention of this exon may be recent in terms of evolution.
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that its deleterious association with cognitive perfor-
mance and dementia could be related to the expres-
sion of this isoform. We first measured the levels of
S100b and S100b2 mRNAs in the brain of 84 AD cases
and 90 controls by semiquantitative RT-PCR. We
observed a strong inverse relationship between the
level of S100b mRNA and the level of S100b2 mRNA
either in the brain of AD cases and controls
(P < 0.0001; see Supplementary material, Figure S4).
This observation suggested a potential regulatory
mechanism controlling the balance of synthesis
between the two isoforms. A 37% decrease in S100b
mRNA (P < 0.0001) and a 41% increase in S100b2
mRNA (P = 0.0007) were measured in AD compared
with controls (Figure 2a). These decreases in S100b
expression, and increases in S100b2 expression, were
greater in women (Figure 2a), in accordance with
previous epidemiological data. As postulated, we
observed that the GG genotype was associated with a
79% increase in S100b2 mRNA levels (P = 0.01)
compared with cases bearing AA and AG genotypes
in AD brains (n = 84, Figure 2b). Consistent with
previous results, this increase was higher in women
(Figure 2b). In control brains, the rs2300403 GG
genotype was not associated with an increase in
S100b2 mRNA level even if a trend may be observed
(þ 20%, data not shown). Therefore, the rs2300403
polymorphism may modulate mechanisms control-
ling S100b2 mRNA synthesis, especially in the brain
of women suffering from AD.
Discussion
We analysed 25 SNPs in the S100b locus and our
findings suggest that at least the rs2300403 SNPs in
S100b increases the risk of low cognitive perfor-
mance, dementia and AD, possibly by favouring a
splicing event leading to the S100b2 isoform in the
brain.
All the P values we reported for the genetic
analyses are not corrected for multiple comparisons.
However, we observed a consistent and highly
significant association of the S100b rs2300403
SNP with low cognitive performances using the
same recessive model in three independent popula-
tions and with the risk of developing dementia,
especially in women, in six independent populations.
We systematically observed throughout our various
experiments, significant and consistent effects.
Reinforcing the coherence of our genetic epidemio-
logy data, we observed a significant association of the
rs2300403 SNP with a higher level of S100b2
expression in the brain of AD cases, again especially
in women.
However, nonetheless and notwithstanding the
significant and consistent effects we have observed,
additional genetic studies involving prospective
cohorts as well as both family-based and large case–
control samples will be required to characterise fully
the role of the rs2300403 SNP. Furthermore, we
cannot exclude the possibility of LD with causal or
more additional pathogenic variants. To evaluate this
possibility, we first screened for all SNPs in the entire
exon 2, intron 2 and exon 3 of the S100b gene,
susceptible to modulate the retention of the new
S100b2 exon. We finally restricted our analyses to
three SNPs (rs1051169, rs2839355 and rs2300403),
exhibiting a significant association with low cognitive
performances in a first screening. In addition with
covariate analyses (see Supplementary material, Table
Table 1 Impact of the rs2300403 SNP on cognitive performance in three populations
ELDNOR Denmark Leiden Combined
n MMS n MMS n MMS n MMS
(a)
AA 399 21.275.3 233 25.773.7 462 25.474.6 1094 23.975.1
AG 331 21.275.1 229 26.073.1 488 25.074.9 1048 24.075.0
GG 85 19.674.9 51 24.973.6 99 24.774.6 235 22.975.1
P 0.03 0.11 0.24 0.002
(b)
AAþAG 730 21.275.2 462 25.873.4 950 25.274.7 2142 24.075.1
GG 85 19.674.9 51 24.973.6 99 24.774.6 235 22.975.1
A¨MMS 1.6 0.9 0.5 1.1
P 0.008 0.04 0.14 0.0005
Table 2 Estimation of the risk of low cognitive performance
according to rs2300403 genotype in the combined population
Combineda n AA AGb GGc
MMSE > 25 1162 554 (0.48) 518 (0.44) 90 (0.08)
MMSE p25 1215 540 (0.44) 530 (0.44) 145 (0.12)
Abbreviation: MMSE, mini mental-state examination.
aP = 0.002.
bOR (AG versus AA) = 1.0, 95 CI% (0.9–1.2), P = 0.60.
cOR (GG versus AA) = 1.7, 95 CI% (1.2–2.3), P = 0.0005.
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S1), we also performed haplotype analysis using the
rs1051169, rs2839355 and rs2300403 SNPs in the
whole ELDNOR study. We investigated the associa-
tion of the resulting haplotypes with low cognitive
performances using the Thesias software.21 This
haplotype analysis assumes a genetic additive model,
whereas the most pertinent model in our case is a
recessive one.21 Nevertheless, despite this limitation,
haplotypes bearing the rs2300403 G allele are system-
atically associated with a lower cognitive perfor-
mance (see Supplementary material, Table S7),
supporting the initial results we observed in the
covariate analysis (see Supplementary material, Table
S1). Altogether, these data support a main effect of the
rs2300403 SNP. However, only functional studies to
evaluate the impact of each SNP on the S100b2
synthesis may help to characterise fully the causal
SNP(s). For instance, the systematic gender effect we
observed, may indicate a hormone-mediated RNA
splicing. Such mechanisms have been already de-
scribed with the oestrogen receptors.27–29
It is not clear how a modification of expression of
the S100b and S100b2 mRNA ratio may favour
biological processes leading to low cognitive perfor-
mance and dementia. A number of observations point
to a beneficial physiological role for S100b. This
suggests that an increase in expression of S100b in
response to injury might be associated with injured
neurons repair, cellular debris clean-up and further
damage resistance (for review, see Donato30). On the
other hand, it has been suggested that chronically
increased S100b levels in the adult brain can be
deleterious. For instance, the elevated tissue level of
S100b in AD brain correlate with the density of
neuritic plaques31,32 and with the density of dys-
trophic neuritis within plaques.33 Peskind et al.34
reported that the cerebro-spinal fluid (CSF) S100b
concentration was significantly higher in 46 mild/
moderate stage AD subjects compared with 25 healthy
controls. This observation may appear to be in
contradiction with our observation of a 47% decrease
in S100b mRNA level in the brain of AD cases.
Table 3 Association of the rs2300403 SNP with dementia or AD by study according to gender or age (%)
Study rs2300403, n (%) OR (95% CI)
n AA AG GG P AG versus AA GG versus AA
Dementia
ELDNOR Cases 203 98 (0.48) 84 (0.41) 21 (0.10) 0.05 1.0 (0.6–1.6) 2.9 (1.0–8.3)
Controls 146 80 (0.55) 61 (0.42) 5 (0.03) NS 0.04
Limeil-Brevannes Cases 127 62 (0.49) 44 (0.35) 21 (0.17) 0.03 1.1 (0.6–1.8) 3.0 (1.3–7.4)
Controls 131 72 (0.49) 51 (0.41) 8 (0.06) NS 0.02
Leiden 85-plus Cases 206 75 (0.36) 109 (0.53) 22 (0.11) 0.06 1.5 (1.0–2.1) 1.8 (1.0–3.3)
Controls 438 202 (0.46) 202 (0.46) 34 (0.08) 0.04 0.06
Combined Cases 536 235 (0.44) 237 (0.44) 64 (0.12) 0.002 1.2(0.9–1.5) 2.1 (1.3–3.3)
Controls 715 354 (0.49) 314 (0.44) 47 (0.07) NS 0.001
Combined men Cases 122 63 (0.52) 50 (0.41) 9 (0.07) NS 0.9 (0.5–1.3) 1.2 (0.5–3.1)
Controls 266 124 (0.47) 126 (0.47) 16 (0.06) NS NS
Combined women Cases 414 172 (0.42) 187 (0.45) 55 (0.13) 0.001 1.2(1.0–1.8) 2.5 (1.5–4.2)
Controls 449 230 (0.51) 188 (0.42) 31 (0.07) 0.06 0.0006
AD
France Cases 604 282 (0.47) 260 (0.43) 62 (0.10) NS 0.9 (0.6–1.5) 1.4 (0.9–2.2)
Controls 567 279 (0.49) 245 (0.43) 43 (0.08) NS 0.10
UK Cases 349 167 (0.48) 133 (0.38) 49 (0.14) 0.04 1.0 (0.7–1.4) 1.7 (1.1–2.8)
Controls 398 205 (0.52) 160 (0.40) 33 (0.08) NS 0.03
USA Cases 197 78 (0.40) 90 (0.46) 29 (0.15) NS 1.2 (0.8–1.9) 2.0 (1.0–4.0)
Controls 197 89 (0.45) 86 (0.44) 22 (0.11) NS 0.05
Combined Cases 1150 527 (0.46) 483 (0.42) 140 (0.12) 0.009 1.0 (0.9–1.3) 1.7 (1.2–2.3)
Controls 1162 573 (0.49) 491 (0.43) 98 (0.08) NS 0.0009
Combined men Cases 452 205 (0.45) 202 (0.45) 45 (0.10) NS 1.2 (0.9–1.6) 1.3 (0.8–2.0)
Controls 526 266 (0.50) 214 (0.41) 46 (0.09) NS NS
Combined women Cases 689 318 (0.46) 277 (0.40) 94 (0.14) 0.006 1.0 (0.8–2.0) 1.9 (1.3–2.8)
Controls 636 307 (0.48) 277 (0.44) 52 (0.08) NS 0.003
Combined agep72 Cases 571 238 (0.48) 210 (0.42) 49 (0.10) NS 1.1 (0.9–1.4) 1.1 (0.7–1.6)
Controls 642 296 (0.50) 239 (0.41) 52 (0.09) NS NS
Combined age > 72 Cases 526 211 (0.46) 183 (0.40) 62 (0.14) 0.0004 1.0 (0.7–1.3) 2.8 (1.7–4.6)
Controls 505 188 (0.50) 166 (0.44) 24 (0.06) NS < 0.0001
Abbreviations: AD, Alzheimer’s disease; NS, not significant; SNP, single nucleotide polymorphism.
ORs were adjusted on age, gender, APOE status and centre when necessary.
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However, in the same paper, Peskind et al.34 also
noticed a nonsignificant 40% decrease in CSF S100b
concentration in 22 more advanced-stage AD subjects
compared with controls. Interestingly, they also
observed a significant positive correlation in all AD
subjects between CSF S100b and MMSE scores and a
significant negative correlation between CSF S100b
and CDR stage.34 At this stage, it is interesting to note
that we observed that in AD brains, the total amount
of hyperphosphorylated tau proteins was weakly
increased when (i) the expression level of S100b
decreased (P = 0.03) or (ii) the expression level of
S100b2 increased (P = 0.009, Figure S7). As AD is a
multifactorial and heterogeneous disease, it is plau-
sible that numerous genes may modulate tau loads in
the brain of AD cases. As a consequence, the
observation that 10% of variation in tau protein levels
may be attributable to S100b2 gene expression, is
relevant. Even if our results are only observational
and do not allow to establish a causative link, the
correlations of the S100b or S100b2 expression levels
with tau level are of interest as neurofibrillary
degeneration may constitute a pathological substrate
for memory loss in normal ageing, mild cognitive
impairment and AD.35,36 Interestingly, in addition to
activation of cytokines, it has been described that
S100b may also play a direct role in tau-related
pathways that are associated with neurodegeneration:
S100bmay be a modulator of tau phosphorylation and
any changes in their interaction could be a factor in
the AD-related hyperphosphorylation.37–39
At this stage, to determine the biological activities
associated with the S100b2 mRNA isoform may
clearly help to understand better the role of S100b
in the dementia process. Indeed, it is unlikely that
this mRNA isoform results from an aberrant splicing
event as this one appears to be relatively frequent, as
observed in EST database (3.2%) and brains of AD
cases (5.8% in average of the total mRNAs produced
from the S100b locus and up to 50% in some cases).
Two possibilities may be hypothesised: (i) the mRNA
isoform may be translated into a protein which differs
by its last 48 aa from S100b. Research for protein
homologies by BLAST or specific domain in the new
C-terminal domain were unsuccessful and to estimate
a possible gain of function of S100b2 compared with
S100b was, as a consequence, not possible. However,
a potential loss of function may be evaluated. The
neurotrophic activities of S100b are dependent on a
disulphide-linked dimeric form of the protein.40–42
Figure 2 (a) Comparison of S100b and S100b2 expression levels (means7s.e.m.) in AD and control brains. (b) Association
between the rs2300403 genotypes and the mRNA expression level of S100b and S100b2 (means7s.e.m.). Non-parametric
Wilcoxon tests were used.
Risk factor of cognitive performance and dementia
J-C Lambert et al
878
Molecular Psychiatry
The number of cysteine residues are not modified
between the S100b and S100b2 isoforms (at codon 68
and 84 and at codon 62 and 84, respectively),
suggesting a conserved ability to form disulphide-
linked dimer. However, the S100b C-terminal domain
is important for certain S100b/target protein interac-
tions.43–45 With this background, one possibility
would be that S100b2 interacts with S100b, modulat-
ing the neurotrophic biological activities normally
associated with the S100b homodimer; (ii) the S100b2
mRNA isoform is finally not translated and is
produced to modulate the S100b mRNA pool, avail-
able for S100b protein production. Such hypothesis
could be supported by the strong correlation existing
between the S100b and S100b2 mRNA levels in the
brain of AD cases. Thus, the next step of this work
will be developing the tools necessary to answer the
biological relevance of the S100b2 mRNA isoform.
More extensive functional testing of S100b2 will be
required to fully characterise the role of the S100b2
mRNA isoform in the physiopathological processes
leading to AD and dementia, and as a consequence to
better determine the role of S100b in these processes.
In conclusion, our results suggest that genetic
variations in S100b are associated with increased risk
of lower cognitive performance, dementia and AD.
These effects are more pronounced in women and
increase with age. This interaction with age reinforces
the hypothesis that S100b plays a role in the
continuum from cognitive impairment to dementia.
Furthermore, this effect may be mediated by a
splicing event leading to a new primate-specific
S100b mRNA isoform. Furthermore, as the S100b
protein has already been implicated in traumatic,
ischaemic and inflammatory brain damage as well as
in neurodegenerative and psychiatric disorders, our
discovery may have major implications for many
human brain pathologies.46–48
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